Onyx Seeks Suitors After Rejecting Amgen’s Bid

July 1 (Bloomberg) -- Onyx Pharmaceuticals, the maker of the cancer drug Nexavar, said it is in contact with other possible acquirers after rejecting an unsolicited $120-a-share cash takeover bid from Amgen Onyx shares surged. Dominic Chu reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)

Facebook's Head of Northern Europe on Brexit's Impact
28:20 - The popularity of mobile among Facebook's U.K. users is helping to draw advertiser interest even as concerns about Brexit remain. Steve Hatch, Facebook's head of Northern Europe, comments in an interview with Bloomberg's Caroline Hyde. (Source: Bloomberg)
  • Full Show: Bloomberg ‹GO› (09/27)
  • The Montage Difference: Defining the Luxury Experience
  • Why JPMorgan Is Getting Into ETFs Now